# Tirzepatide

> FDA-approved GLP-1/GIP dual agonist.

Source: https://peptides.cafe/peptide/tirzepatide
Category: Metabolic · Incretin
Tag: Weight loss

## Mechanism
A dual agonist of the GLP-1 and GIP receptors. The combined incretin action improves glucose control and produces greater weight loss than GLP-1 monotherapy in head-to-head trials.

## Research areas
- Type 2 diabetes (Mounjaro)
- Chronic weight management (Zepbound)
- Sleep apnea in obesity (recent approval)

## Common research protocols
- Weekly subcutaneous clinical use: Stepwise dose escalation in approved indications.

## Study summaries
- "Tirzepatide once weekly for weight management (SURMOUNT-1)" — New England Journal of Medicine (2022): Up to ~21% mean weight loss at 72 weeks at the highest dose.

## Considerations
- FDA-approved; requires prescription and physician oversight.
- GI side effects are dose-limiting.
- Compounded versions are not FDA-evaluated.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.